Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report [Internet].

McDonagh MS, Peterson K, Thakurta S, Low A.

Portland (OR): Oregon Health & Science University; 2011 Dec.

2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

4.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
5.

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Epstein T, Patsopoulos NA, Weiser M.

Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD005041.

PMID:
25230710
6.

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C.

Cochrane Database Syst Rev. 2015 Nov 25;(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Review.

7.

Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.

Chan E, Fogler JM, Hammerness PG.

JAMA. 2016 May 10;315(18):1997-2008. doi: 10.1001/jama.2016.5453. Review.

PMID:
27163988
8.

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.

Otasowie J, Castells X, Ehimare UP, Smith CH.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD006997. doi: 10.1002/14651858.CD006997.pub2. Review.

PMID:
25238582
10.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

11.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

12.

Drug Class Review: Neuropathic Pain: Final Update 1 Report [Internet].

Selph S, Carson S, Fu R, Thakurta S, Low A, McDonagh M.

Portland (OR): Oregon Health & Science University; 2011 Jun.

13.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.

Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

CNS Drugs. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. Review.

PMID:
22712698
14.

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.

Pringsheim T, Steeves T.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD007990. doi: 10.1002/14651858.CD007990.pub2. Review.

PMID:
21491404
15.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
16.

Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Spiller HA, Hays HL, Aleguas A Jr.

CNS Drugs. 2013 Jul;27(7):531-43. doi: 10.1007/s40263-013-0084-8. Review.

PMID:
23757186
17.

Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.

Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M.

BMC Psychiatry. 2013 Sep 27;13:237. doi: 10.1186/1471-244X-13-237. Review. Erratum in: BMC Psychiatry. 2015;15:202.

18.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
19.
20.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
Items per page

Supplemental Content

Write to the Help Desk